18th May 2022

Celix Pharma announces the launch of its first product in the UK – Fesoterodine PR Tablets. 

Celix Pharma is excited to announce the launch of Fesoterodine fumarate 4mg, 8mg prolonged-release Tablets in the UK. Both strengths are available in blister (patient) packs of 28 tablets.   

Fesoterodine fumarate is indicated in adults for treatment of the symptoms associated with overactive bladder, a condition in which the bladder muscles contract uncontrollably and cause frequent urination, urgent need to urinate, and inability to control urination. Fesoterodine belongs to a class of medications called antimuscarinics, which work by relaxing the bladder muscles(1).

Commenting on this launch, Subir Kohli, Co-founder & CEO said, “As our first product launch, Fesoterodine PR tablets represents a significant milestone in the evolution of Celix Pharma. This product is intended for the retail pharmacy segment. The team at Celix Pharma has put considerable efforts to build a product pipeline for both the retail and hospital pharmacy channels and it’s great to see this bearing fruit. In under 2 years of operations, the company has filed over 15 products, received 6 approvals and now has its first product on the market.”   

VS Vasudevan (Director on the Board of Celix Pharma) added, “It is impressive to see how the business has shaped in the last 2 years with the focussed efforts of the founding team. Looking forward to more product launches as Celix continues its journey of becoming a meaningful player in the UK generic market”. 

1. Source: MedlinePlus (https://medlineplus.gov/druginfo/meds/a609021.html/)